Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6316 to 6330 of 8908 results

  1. Hidden spine fractures could be spotted earlier after NICE recommendation

    NICE is recommending that quick spine checks are added to routine bone scans to help spot hidden fractures earlier and prevent serious complications.

  2. Digital platforms recommended to help people manage their asthma

    People with asthma could benefit from digital tools on their phones or tablets to help them better manage their condition, states our draft guidance published today.

  3. New sepsis guideline targets faster, tailored treatments to benefit patients

    Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.

  4. New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier

    More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.

  5. NICE recommends new treatment option for highly active multiple sclerosis

    Thousands of people living with a form of multiple sclerosis (MS) will benefit from greater treatment choice, following new guidance from NICE.

  6. NICE announces Professor Jonathan Benger as new Chief Executive

    NICE Chairman, Sharmila Nebhrajani, today announced Professor Jonathan Benger CBE as incoming chief executive, with effect from Friday 19 December 2025 taking over from Dr Samantha Roberts.

  7. Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

    Discontinued Reference number: GID-TA10474

  8. Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]

    Discontinued Reference number: GID-TA10480

  9. Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]

    In development Reference number: GID-TA10483 Expected publication date: TBC

  10. Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

    Discontinued Reference number: GID-TA10484

  11. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development Reference number: GID-TA10489 Expected publication date: TBC

  12. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

    Discontinued Reference number: GID-TA10490

  13. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

    Discontinued Reference number: GID-TA10492

  14. Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]

    Discontinued Reference number: GID-TA10494

  15. Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

    Discontinued Reference number: GID-TA10495